Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tania Jain

Showing results (51-60 of 118) with videos related to

Pageof 12
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 28, 2015
Clostridium Difficile Colonization in Hematopoietic Stem Cell Transplant Recipients: A Prospective Study of the Epidemiology and Outcomes Involving Toxigenic and Nontoxigenic StrainsTania Jain, Christopher Croswell, Varinia Urday-Cornejo, et al.
Leukemia & Lymphoma|January 11, 2019
Early fluctuations in busulfan levels with therapeutic dose monitoring during allogeneic stem cell transplantation: do they matter?Tania Jain, Katie L Kunze, Banveet K Khetarpal, et al.
Transplantation and Cellular Therapy|April 14, 2024
ASTCT Committee on Practice Guidelines Survey on Evaluation and Management of Relapsed/Refractory Multiple Myeloma after Failure of Chimeric Antigen Receptor T Cell TherapyHamza Hashmi, Ambuj Kumar, Mohamed A Kharfan-Dabaja, et al.
Leukemia & Lymphoma|July 7, 2018
Single dose versus multiple doses of rituximab for preemptive therapy of Epstein-Barr virus reactivation after hematopoietic cell transplantationTania Jain, Heidi E Kosiorek, Thomas E Grys, et al.
Open Forum Infectious Diseases|February 4, 2021
Tocilizumab for the Treatment of COVID-19 Among Hospitalized Patients: A Matched Retrospective Cohort AnalysisElisa H Ignatius, Kunbo Wang, Andrew Karaba, et al.
Transplantation and Cellular Therapy|July 31, 2024
Best Practice Considerations by The American Society of Transplant and Cellular Therapy: Infection Prevention and Management After Chimeric Antigen Receptor T Cell Therapy for Hematological MalignanciesZainab Shahid, Tania Jain, Veronica Dioverti, et al.
Hematological Oncology|June 28, 2020
Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignanciesTariq I Mughal, Naveen Pemmaraju, Bethan Psaila, et al.
Transplantation and Cellular Therapy|November 11, 2023
Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular TherapyOlalekan O Oluwole, Bhagirathbhai Dholaria, Tristan E Knight, et al.
Anti-Cancer Drugs|August 16, 2019
Monoclonal antibody utilization characteristics in patients with multiple myelomaSikander Ailawadhi, Taimur Sher, Abdel-Ghani Azzouqa, et al.
Blood|January 21, 2026
Lymphoid malignancy and clonality in the POT1-mediated long telomere syndromeHannah R Davidson-Swinton, Sheila Iyer, Anna Kolchinski, et al.
Pageof 12

Showing results (51-60 of 118) with videos related to

Sort By:
Pageof 12
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 28, 2015
Clostridium Difficile Colonization in Hematopoietic Stem Cell Transplant Recipients: A Prospective Study of the Epidemiology and Outcomes Involving Toxigenic and Nontoxigenic StrainsTania Jain, Christopher Croswell, Varinia Urday-Cornejo, et al.
Leukemia & Lymphoma|January 11, 2019
Early fluctuations in busulfan levels with therapeutic dose monitoring during allogeneic stem cell transplantation: do they matter?Tania Jain, Katie L Kunze, Banveet K Khetarpal, et al.
Transplantation and Cellular Therapy|April 14, 2024
ASTCT Committee on Practice Guidelines Survey on Evaluation and Management of Relapsed/Refractory Multiple Myeloma after Failure of Chimeric Antigen Receptor T Cell TherapyHamza Hashmi, Ambuj Kumar, Mohamed A Kharfan-Dabaja, et al.
Leukemia & Lymphoma|July 7, 2018
Single dose versus multiple doses of rituximab for preemptive therapy of Epstein-Barr virus reactivation after hematopoietic cell transplantationTania Jain, Heidi E Kosiorek, Thomas E Grys, et al.
Open Forum Infectious Diseases|February 4, 2021
Tocilizumab for the Treatment of COVID-19 Among Hospitalized Patients: A Matched Retrospective Cohort AnalysisElisa H Ignatius, Kunbo Wang, Andrew Karaba, et al.
Transplantation and Cellular Therapy|July 31, 2024
Best Practice Considerations by The American Society of Transplant and Cellular Therapy: Infection Prevention and Management After Chimeric Antigen Receptor T Cell Therapy for Hematological MalignanciesZainab Shahid, Tania Jain, Veronica Dioverti, et al.
Hematological Oncology|June 28, 2020
Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignanciesTariq I Mughal, Naveen Pemmaraju, Bethan Psaila, et al.
Transplantation and Cellular Therapy|November 11, 2023
Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular TherapyOlalekan O Oluwole, Bhagirathbhai Dholaria, Tristan E Knight, et al.
Anti-Cancer Drugs|August 16, 2019
Monoclonal antibody utilization characteristics in patients with multiple myelomaSikander Ailawadhi, Taimur Sher, Abdel-Ghani Azzouqa, et al.
Blood|January 21, 2026
Lymphoid malignancy and clonality in the POT1-mediated long telomere syndromeHannah R Davidson-Swinton, Sheila Iyer, Anna Kolchinski, et al.
Pageof 12